U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 721 - 730 of 21518 results

Status:
Investigational
Source:
NCT02511197: Early Phase 1 Interventional Unknown status Pulmonary Fibrosis, Unspecified
(2015)
Source URL:

Class (Stereo):
CHEMICAL (EPIMERIC)

Status:
Investigational
Source:
INN:cloticasone
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Cloticasone is a synthetic glucocorticoid corticosteroid, an analog of fluticasone. Cloticasone was discovered by Glaxo in the 1980s and claimed to be useful as an antiinflammation agent.
Status:
Investigational
Source:
NCT00016354: Phase 1 Interventional Completed Unspecified Adult Solid Tumor, Protocol Specific
(2001)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Status:
Investigational
Source:
INN:egalognastat [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Status:
Investigational
Source:
INN:lividomycin
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Lividomycin is the antibacterial agent produced by Streptomyces lividus. It is aminoglycoside antibiotic. Lividomycin binds to bacterial ribosomes and inhibits protein synthesis. In vitro development of resistance to lividomycin in P. aeruginosa and M. tuberculosis was much slower than that to kanamycin, but was comparable in Staphylococcus aureus. Lividomycin showed a positive protecting effect for the experimental infections in mice with several bacteria such as S. aureus, P. aeruginosa, Klebsiella pneumoniae and Escherichia coli. It was fairly effective for the experimental infection with the kanamycin-resistant strains of E. coli and P. aeruginosa producing the kanamycin-phosphorylating enzyme.
Status:
Investigational
Source:
INN:tropabazate
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Tropabazate is a narcosis potentiator, tranquilliser.
Status:
Investigational
Source:
INN:dexefaroxan
Source URL:

Class (Stereo):
CHEMICAL (RACEMIC)


Efaroxan (RX 821037) is a potent and selective alpha(2)-adrenoceptor antagonist. Additionally, Efaroxan is a selective antagonist at the imidazoline I1 receptor. Efaroxan promotes insulin secretion, in the absence of exogenous agonists, by a mechanism that involves inhibition of ATP-regulated K+ channels. Efaroxan was in clinical trials for the treatment of diabetes mellitus however its development has been discontinued.
Status:
Investigational
Source:
INN:ursulcholic acid [INN]
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Ursulcholic acid is a soluble form of ursodeoxycholic acid. It is an anticholinergic agent.
Status:
Investigational
Source:
INN:revatropate
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)

Revatropate is a muscarinic antagonist with selectivity for M1 and M3 receptor subtypes. Significant improvement in airway function was shown in horses with heaves after inhalation of revatropate, and it was found to be a safe and effective bronchodilator. Early clinical studies in chronic obstructive airway disease (COAD) patients also showed that inhaled revatropate was an effective bronchodilator, and well tolerated.
Status:
Investigational
Source:
NCT04172532: Phase 1/Phase 2 Interventional Recruiting Locally Advanced Pancreatic Adenocarcinoma
(2021)
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)